Dimerix Limited (ASX:DXB) Reports Half-Year Financial Results
Financial Performance
Dimerix Limited (ASX:DXB) reported revenues from ordinary activities increased by 113% to $476,620 for the half-year ended 31 December 2024. However, the loss after tax attributable to owners rose by 93% to $12,907,398. The company did not pay, recommend, or declare any dividends during the current financial period.
Operational Highlights
The company ended the half-year with a cash reserve of $21.1 million. Dimerix continued to advance its DMX-200 clinical program in Focal Segmental Glomerulosclerosis (FSGS) and entered an exclusive development and licensing agreement with FUSO Pharmaceutical Industries Ltd. in Japan, potentially bringing in up to $107 million in milestones and royalties.
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.